Full-Life Technologies Raises $77M for Radiopharmaceutical Innovation

Full-Life Technologies Limited has secured $77,000,000 in a new funding round from investors, bolstering its efforts as a global radiopharmaceutical company. This significant capital raise underscores investor confidence in Full-Life’s strategy to become a fully integrated player in the radiopharmaceutical sector, spanning research, development, production, and commercialization. The company, with operations in Belgium, Germany, and China, is dedicated to delivering clinical impact for patients by addressing core issues in radiopharmaceuticals. Full-Life aims to own the entire value chain, leveraging innovative research to target future treatments. Its team comprises experienced entrepreneurs and scientists with a demonstrated track record in life sciences, as well as radioisotope research and clinical development. The $77,000,000 in investment capital will primarily be allocated to accelerating Full-Life’s research and development initiatives, particularly its innovative approach to radiopharmaceutical treatments. This funding is crucial for scaling its global operations across its existing hubs and advancing its pipeline of therapies. The company plans to expand its capabilities in both production and commercialization to ensure a broader reach for its future products. This injection of capital is expected to empower Full-Life Technologies to strengthen its position in the competitive radiopharmaceutical market. By focusing on integrated value chain ownership and innovative R&D, the company aims to expedite the delivery of novel treatments. Looking ahead, Full-Life Technologies is poised to expand its impact within the radiopharmaceutical landscape, driven by this new investment. The company's growth plans are centered on leveraging its integrated model to bring groundbreaking solutions to patients worldwide.